罗格列酮联合二甲双胍治疗2型糖尿病临床疗效

摘要

目的:探讨罗格列酮联合二甲双胍治疗2型糖尿病的临床疗效和安全性.方法:选取2008年1月～2010年1月我院诊断的2型糖尿病患者60例,给予罗格列酮和二甲双胍缓释片联合治疗.观察60例患者治疗前后空腹血糖(FBG)、餐后2 h血糖、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、胰岛素抵抗指数、胰岛素敏感指数变化,观察治疗过程中不良反应发生情况.结果:60例患者治疗后FBG、餐后2 h血糖、HbA1c,TC、TG水平和胰岛素抵抗指数与治疗前比较均下降,差异有统计学意义(P<0.05).治疗后60例患者胰岛素敏感指数较治疗前升高,差异有统计学意义(P<0.05).60例患者治疗过程中发生低血糖4例,下肢水肿2例,胃肠道反应1例,不良反应发生率为11.7%.结论:罗格列酮联合二甲双胍治疗2型糖尿病可以有效的降低患者血糖水平,改善血脂代谢和胰岛素抵抗,不良反应较少.%Objective: To explore the therapeutic effect of Rosiglitazone combined with Metformin in the treatment of type 2 diabetes.Methods: 60 patients who were diagnosed type 2 diabetes were given Rosiglitazone combined with Metformin therapy.FBG, 2 h BG, HbA1c, TC, TG, insulin resistance index, insulin sensitivity index before and after the treatment, adverse reaction conditions were observed.Results: 60 patients after treatment FBG, 2 h postprandial blood sugar, HbA1c,TC, TG level and insulin resistance index significantly decreased compared with before treatment (P＜0.05).After the treatment insulin sensitivity index significantly increased compared with before treatment (P＜0.05).4 cases of patients had hypoglycemia, 2 cases of lower limb edema, 1 case of gastrointestinal reaction, adverse reaction rate was 11.7％.Conclusion:Rosiglitazone combined with Metformin for type 2 diabetes patients can effectively reduce blood glucose levels, improve blood lipid metabolism and insulin resistance and adverse reaction is less.